Pasquale Florio

Pasquale Florio

Auto-generated profile, based on publicly available information

Pasquale Florio

Department of Pediatrics, Obstetrics and Reproductive Medicine, Section of Obstetrics and Gynecology, University of Siena, Siena, Italy

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Current Opinion in Obstetrics and Gynecology
Verified
Journal Article
Closed access
PFPasquale Florio
Pasquale Florio
MFMarco Filippeschi
Marco Filippeschi
IMIrene Moncini
Irene Moncini
EMElena Marra
Elena Marra
MFMario Franchini
Mario Franchini
GGGiampietro Gubbini
Giampietro Gubbini
To review the treatments of the cesarean-induced isthmocele in restoring infertility, associated techniques, and the risks of complications associated with their use. Isthmocele is a reservoir-like pouch defect on the anterior wall of the uterine isthmus located at the site of a previous cesarean delivery scar. The flow of menstrual blood through the cervix may be slowed by the presence of isthmocele, as the blood may accumulate in the niche because of the presence of fibrotic tissue, causing pelvic pain in the suprapubic area. Moreover, persistence of the menstrual blood after menstruation in the cervix may negatively influence the mucus quality and sperm quality, obstruct sperm transport through the cervical canal, interfere with embryo implantation, leading to secondary infertility. The removal of the local inflamed tissue may be performed by laparoscopic, combined laparoscopic-vaginal, or vaginal surgery, and operative hysteroscopy, a minimally invasive approach to improve symptoms and restore fertility. Isthmocele occurs after cesarean section, a common method of delivery and one of the most frequent surgical procedures, so that its upward incidence appears likely to continue in the near future. Because of its minimal invasiveness, resectoscopy may be the better choice for treatment, yielding good therapeutic results.

23 June 2010 in Gynecological Endocrinology
Verified
Journal Article
Closed access
PFPasquale Florio
Pasquale Florio
GGGiampiero Gubbini
Giampiero Gubbini
EMElena Marra
Elena Marra
DDDaniela Dores
Daniela Dores
DNDaniela Nascetti
Daniela Nascetti
FPFelice Petraglia
Felice Petraglia
In a retrospective case-control study, we compared the effectiveness of hysteroscopic correction and hormonal treatment to improve symptoms [postmestrual abnormal uterine bleeding (PAUB), pelvic pain localized in suprapubic site] associated with isthmocele. Women (n = 39; mean age ± SD, 35 ± 4.1 years) were subdivided in Group A [patients (n = 19) subjected to hysteroscopic surgery (isthmoplasty)] and, Group B [women (n = 20) undergoing hormonal treatment consisting of one oral tablet containing 0.075 mg of Gestodene and 0.030 mg of Ethynylestradiol for 21 days, followed by 7 days of suspension]. Resolution and/or improvement of menstrual disorders; patients degree of satisfaction with the treatment were measured 3 months later, by office hysteroscopy (Grop A) or phone call. PAUB and pelvic pain resolution was achieved in all patients: Group A had significant lower numbers of days of menstrual bleeding (P < 0.001), prevalence of pelvic pain in the suprapubic area (P = 0.04) and, higher degree of satisfaction (P < 0.001) compared to Group B. In conclusion, resectoscopic surgery is a valid way to treat patients with symptoms of prolonged postmenstrual uterine bleeding caused by isthmocele. Data from this study also indicate that resectoscopy may be the first choice because it is minimally invasive and yields good therapeutic results.

1 September 2007 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
PFPasquale Florio
Pasquale Florio
FRFernando M Reis
Fernando M Reis
PTPaulo B. Torres
Paulo B. Torres
FCFrancesco Calonaci
Francesco Calonaci
PTPaolo Toti
Paolo Toti
FPFelice Petraglia
Felice Petraglia
OBJECTIVE: Urocortin is a neuropeptide, member of the corticotropin-releasing hormone family, that is produced by the human endometrium. Ovarian endometrioma is a prevalent gynecologic disorder still lacking specific serum markers. In the present study we measured systemic levels of urocortin to assess the diagnostic performance of its determination in distinguishing endometriomas from other benign ovarian cysts. METHODS: Plasma urocortin was measured by radioimmunoassay in women with ovarian endometrioma (n=40) and in women with benign, nonendometriotic ovarian cysts (n=40). The diagnostic accuracy of urocortin measurement was evaluated by receiver operating characteristic curve and compared with the standard marker, CA 125. To support the local origin of the peptide, we also evaluated its localization in endometriomas by immunohistochemistry and its concentrations in cyst fluid and peritoneal fluid of 12 women with endometrioma. RESULTS: Plasma urocortin levels were twice as high in women with endometrioma (median 49 pg/mL, interquartile range 41–63 pg/mL) than in the control group (19 [15–23] pg/mL, P<.001) and significantly higher in the cystic content of endometriomas than in the peritoneal fluid and plasma (P<.05). The peptide was immunolocalized in endometrioma glands and stromal capillary vessels. Elevated plasma urocortin levels detected 88% of the cases of endometrioma with 90% specificity, whereas CA 125 detected only 65% of the cases with the same specificity. CONCLUSION: Plasma urocortin is increased in women with endometriomas, and its measurement may be useful for the differential diagnosis of endometrioma compared with other benign ovarian cysts. LEVEL OF EVIDENCE: II

1 July 2013 in Reproductive Sciences
Verified
Journal Article
Closed access
LNLuigi Nappi
Luigi Nappi
ASAttilio Di Spiezio Sardo
Attilio Di Spiezio Sardo
MSMarialuigia Spinelli
Marialuigia Spinelli
MGMaurizio Guida
Maurizio Guida
LMLuca Mencaglia
Luca Mencaglia
PFPasquale Florio
Pasquale Florio

1 April 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
RNRomina Novembri
Romina Novembri
LBLavinia Estrela Borges
Lavinia Estrela Borges
PCPatrizia Carrarelli
Patrizia Carrarelli
ARAna Luiza Lunardi Rocha
Ana Luiza Lunardi Rocha
FPFlavio De Pascalis
Flavio De Pascalis
FPFelice Petraglia
Felice Petraglia
Context: Women with endometriosis have altered endometrial function. CRH and urocortin (Ucn) are neuropeptides produced by human endometrium and modulate endometrial decidualization. Objective: To evaluate endometrial mRNA expression of CRH and Ucn, their role in in vitro decidualization of cultured human endometrial stromal cells (HESCs) in patients with endometriosis, and the role of CRH receptors (CHR-Rs). Design: Obstetrics and Gynecology, University of Siena. Patients: Endometrial specimens were obtained from patients with and without endometriosis. Interventions: Endometrial biopsy obtained at both phases of menstrual cycle. In vitro decidualization of HESCs collected from endometriosis or control was done in the presence of CRH, Ucn, or CRH receptor type 1 (CRH-R1, antalarmin) or type 2 (CRH-R2, astressin 2b) antagonists. Outcome Measures: Endometrial mRNA expression of CRH and Ucn during endometrial cycle; prolactin, CRH-R1, and CRH-R2 mRNA expression during in vitro decidualization. Results: In healthy women CRH and Ucn expression were significantly higher (P < 0.05) in secretory than in proliferative phase; no differences were observed in endometriotic women. During in vitro decidualization, prolactin mRNA expression and release in endometriosis was lower than in control (P < 0.001). CRH and Ucn were able to significantly increase (P < 0.01) prolactin release only in control group; moreover, in this group antalarmin reduced prolactin release (P < 0.01). CRH-R1 mRNA expression increased during in vitro decidualization of HESCs in control (P < 0.01) but not in endometriosis. Conclusions: Women with endometriosis show an impaired endometrial expression of CRH and Ucn mRNA, and these neuropeptides are no more active in modulating the in vitro decidualization of HESCs, associated with a reduced expression of CRH-R1 mRNA.

1 April 2010 in Reproductive Sciences
Verified
Journal Article
Closed access
PFPasquale Florio
Pasquale Florio
MGMassimo Gabbanini
Massimo Gabbanini
LBLavinia E. Borges
Lavinia E. Borges
LBLorella Bonaccorsi
Lorella Bonaccorsi
SPSerena Pinzauti
Serena Pinzauti
FPFelice Petraglia
Felice Petraglia